The Ptgs2 Knockout RM-1 Cell Line is a CRISPR/Cas9-edited murine prostate cancer cell model featuring targeted disruption of the Ptgs2 gene, which encodes cyclooxygenase-2 (COX-2). By abolishing COX-2 enzymatic function, this cell line enables researchers to dissect prostaglandin-dependent pathways without confounding pharmacological inhibition. It serves as a defined, loss-of-function system for investigating COX-2 contributions to tumor biology, inflammation, and signal transduction in a genetically tractable background.
The parental RM-1 cell line was derived from a C57BL/6 mouse prostate adenocarcinoma and is widely used as a syngeneic model for studying prostate cancer progression, metastasis, and host-tumor interactions. RM-1 cells exhibit aggressive in vivo growth and retain key features of androgen-independent prostate cancer, making them suitable for evaluating therapeutic strategies and tumor microenvironment dynamics. Their murine origin allows for immunocompetent in vivo studies, facilitating research into immune cell infiltration, cytokine networks, and tumor-immune crosstalk.
COX-2 catalyzes the conversion of arachidonic acid to prostaglandin H2, the precursor for multiple prostanoids including PGE2, PGD2, PGF2??, and TXA2. Ptgs2 expression is transcriptionally upregulated by pro-inflammatory and mitogenic stimuli such as IL-1??, TNF-??, EGF, and PDGF, acting through NF-??B, MAPK, and Src pathways. Downstream, PGE2 exerts pleiotropic effects via EP1?CEP4 receptors, coupling to cAMP-PKA, PI3K/AKT, MAPK/ERK, and Wnt/??-catenin cascades. COX-2 also cooperates with ??-catenin and HIF-1?? to promote transcription of VEGF, MMPs, and Bcl-2, integrating inflammatory and oncogenic signals.
In the RM-1 prostate cancer context, Ptgs2 knockout eliminates COX-2-mediated prostaglandin synthesis, thereby blunting paracrine and autocrine loops that drive proliferation, survival, and angiogenesis. Loss of PGE2 signaling reduces EP receptor-mediated activation of cAMP-PKA and ERK pathways, impairing cell cycle progression and migratory capacity. Additionally, dampened NF-??B and PI3K/AKT activity attenuates expression of pro-survival factors, sensitizing cells to apoptotic stimuli. This model thus recapitulates the consequences of COX-2 ablation in a tumorigenic background, enabling dissection of tumor-intrinsic versus microenvironmental roles.
This cell line is ideally suited for mechanistic studies of COX-2 in prostate cancer, including analysis of tumor cell proliferation (MTT assay), migration and invasion (Transwell assays), and xenograft tumor growth. It facilitates investigation of NSAID mechanisms and COX-2-targeted therapies, as well as the role of prostaglandins in tumor-associated inflammation and angiogenesis. Researchers can combine standard assays such as PGE2 ELISA, Western blotting for COX-2 and phospho-ERK/AKT, RT-qPCR for downstream targets, and flow cytometry for apoptosis with chromatin immunoprecipitation (ChIP-qPCR) to assess NF-??B binding. The model also supports immuno-oncology studies in syngeneic hosts. For further information, please contact Ascent Research.
